CLINICAL PHARMACOLOGY OF ANTI-INFLUENZA DRUGS
This review describes the basic properties and mechanisms of action of anti-influenza drugs. The current classification of this group of drugs is shown. The spectrum of activity, pharmacokinetics, adverse reactions, indications and contra-indications for use, dosing regimen of the most commonly used drugs (oseltamivir, zanamivir, rimantadine, amantadine, umifenovir, imidazolyl etanamid of pentandioic acid) were submitted. In the pharmaceutical market of the Republic of Belarus a new Russian antiviral drug - imidazolyl etanamid of pentandioic acid (Ingavirin <sup>®</sup> ) became available. Results of laboratory, preclinical and clinical studies of Ingavirin <sup>®</sup>, which number 18 scientific publications and cover approximately 500 patients and more than 7 years of experience in the use of drugs in medical practice as a therapeutic and prophylactic remedy of influenza in adults are evidence of its efficacy and good tolerability. Comparative analysis of the results of the treatment of influenza by Ingavirin <sup>®</sup>, Tamiflu <sup>®</sup> and Arbidol <sup>®</sup> showed their comparable high clinical efficacy.